Global Laboratory Animal Model Market Size, Share, and Trends Analysis Report – Industry Overview and Forecast to 2032

 Laboratory Animal Model Market Size

• The global laboratory animal model market was valued at USD 904.38 million in 2024 and is expected to reach USD 1.65 million by 2032
• During the forecast period of 2025 to 2032 the market is likely to grow at a CAGR of 7.30%, primarily driven by the rising preclinical trial investment
• This growth is driven by factors such as the growing R&D, and technological advancements

Laboratory Animal Model Market Analysis

• Laboratory animal models are essential tools used in biomedical research, drug development, and toxicity testing, enabling researchers to study human diseases, evaluate potential treatments, and assess the safety of new medical products. These models include a variety of species such as rodents (mice, rats), rabbits, guinea pigs, and non-human primates, each chosen based on the research needs and objectives
• The demand for laboratory animal models is driven by several factors, including the growing need for preclinical testing in drug discovery and development, the rise in chronic diseases such as cancer, neurological disorders, and cardiovascular diseases, and the increasing focus on personalized medicine. Pharmaceutical and biotechnology companies rely heavily on these models for testing the efficacy and safety of new drugs before they are introduced to human clinical trials
• North America is one of the dominant markets for laboratory animal models due to its advanced healthcare infrastructure, high research investment, and well-established pharmaceutical and biotechnology industries. U.S., in particular, remains a leader in drug discovery and development, and its demand for animal models for both regulatory testing and R&D purposes continues to drive market growth. In addition, major research institutes and contract research organizations (CROs) in the region contribute to this demand 
  • For instance, U.S. is home to numerous large pharmaceutical companies and research organizations, where the use of laboratory animals is integral to the early stages of drug development. These institutions not only utilize animal models extensively but also lead innovations in the field, such as developing genetically modified models for specific diseases 
• Asia-Pacific is expected to witness the highest growth in the laboratory animal model market, driven by rapid expansion in pharmaceutical and biotech industries in countries such as China, India, and Japan. The region's growing healthcare and research infrastructure, coupled with the rising need for preclinical testing due to increased R&D activities, are pivotal factors fuelling this market growth
• Globally, laboratory animal models are regarded as an indispensable asset in the preclinical research process. As regulations become more stringent and research efforts become more specialized, the role of laboratory animals in advancing scientific knowledge and facilitating drug approval remains critical. This trend underscores their continued importance in supporting the development of new and more effective treatments across various therapeutic areas

Report Scope and Laboratory Animal Model Market Segmentation   

Laboratory Animal Model Market Trends

“Increasing Adoption of Advanced Technologies in Laboratory Animal Models”

• A prominent trend in the global laboratory animal model market is the growing adoption of advanced technologies, such as genetically modified models, CRISPR gene editing, and 3D bioprinting
• These technologies enhance the precision of research by enabling the development of animal models that more accurately replicate human diseases, improving the reliability of preclinical testing for drug development 
  • For instance, the use of genetically modified animal models allows researchers to simulate specific human genetic conditions, helping in targeted drug discovery and reducing the reliance on human trials 
• 3D bioprinting has emerged as a promising tool for creating more complex and human-like tissue models, accelerating the development of regenerative medicine and personalized therapies
• The integration of these technologies is transforming the way laboratory animal models are used, enhancing research capabilities, and improving the effectiveness of drug testing and disease modeling
• This trend is not only boosting the demand for customized animal models but also opening new opportunities in personalized medicine and biopharmaceutical research, contributing significantly to the market's growth

Laboratory Animal Model Market Dynamics

Driver

“Rising Demand for Laboratory Animal Models in Biomedical Research”

• The growing need for laboratory animal models in various research fields, such as drug discovery, toxicology testing, cancer research, and neurological studies, is a primary factor driving the demand for these models
• As the complexity of human diseases increases, there is a growing reliance on animal models to replicate conditions such as cancer, neurological disorders, and immune-related diseases, to facilitate the development of novel treatments
• The increasing prevalence of chronic diseases, coupled with the rising need for effective therapeutic solutions, has amplified the demand for animal models to improve the accuracy and efficiency of research
• With advancements in technology, laboratory animal models can now be more genetically specific and disease-relevant, further driving their demand in both pharmaceutical and biotechnology industries

For instance,

• According to a 2024 article published by the National Institutes of Health, animal models are crucial for studying the effects of new treatments on cancer, which is expected to be one of the leading drivers of pharmaceutical research. This enhances the relevance and need for animal models in research studies 
• The growing complexity of human diseases, increasing chronic conditions, and advancements in technology are driving the demand for laboratory animal models in drug discovery, cancer research, and other therapeutic studies

Opportunity

“Growing Focus on Customization and Advanced Technologies”

• There is an increasing focus on the customization of animal models for more accurate disease representation, allowing researchers to develop personalized models tailored to specific therapeutic targets and genetic conditions
• Technologies such as CRISPR gene editing and 3D bioprinting are providing new opportunities to create more accurate and specific models, which is expanding the potential applications of laboratory animal models in personalized medicine, gene therapy, and regenerative medicine
• Furthermore, genetically modified animal models are expected to gain greater traction in various sectors, including the pharmaceutical industry, as they offer more precise results in testing drugs and treatments

For instance,

• In December 2024, an article published by ScienceDirect highlighted that the advancement of technologies such as CRISPR has enabled the creation of highly specific animal models for neurological diseases and cancer research, leading to enhanced therapeutic breakthroughs and opportunities for more effective drug testing 
• The growing focus on customizing animal models using advanced technologies such as CRISPR gene editing and 3D bioprinting is driving their adoption in personalized medicine, gene therapy, and regenerative medicine, with genetically modified models offering more precise results for drug testing and treatment development

Restraint/Challenge

“Ethical Concerns and Regulatory Challenges in Laboratory Animal Use”

• Ethical concerns surrounding the use of animals in research continue to present significant challenges to the laboratory animal model market. Increasing awareness and advocacy around animal welfare have led to stricter regulations on animal testing in various regions
• Regulatory hurdles, such as the EU’s Directive 2010/63/EU, require more rigorous scrutiny and approval processes for animal testing, which can delay the introduction of new models and increase the cost of research
• These regulatory and ethical constraints can lead to slower market penetration and increase costs associated with compliance, limiting the accessibility of animal models for small research firms or institutions in developing regions

For instance,

• According to a 2024 report from The National Institute for Health Research, the introduction of more stringent regulations on animal testing in Europe is causing delays in drug development processes and increasing operational costs, which can deter smaller firms from adopting animal models for research 
• These dynamics significantly influence the laboratory animal model market, shaping the growth and adoption of animal models across various industries

Laboratory Animal Model Market Scope

The market is segmented on the basis of animal type, application and end user.

Laboratory Animal Model Market Regional Analysis

“North America is the Dominant Region in the Laboratory Animal Model Market”

• North America leads the global laboratory animal model market due to its advanced healthcare infrastructure, the high adoption of cutting-edge technologies, and the strong presence of key industry players
• U.S. holds a significant share, driven by increased demand for high-precision research procedures, rising prevalence of chronic diseases, and continuous advancements in research techniques across various fields such as cancer, neurological, and immunological studies
• The well-established reimbursement policies, coupled with growing investments in R&D by leading pharmaceutical and biotechnology companies, further strengthen the market's position
• In addition, the increasing focus on preclinical studies and the high adoption of advanced animal models for drug discovery and development contribute to the region’s dominance

“Asia-Pacific is Projected to Register the Highest Growth Rate”

• Asia-Pacific is projected to experience the highest growth rate in the laboratory animal model market due to rapid advancements in healthcare infrastructure, increased awareness about research advancements, and rising investment in research activities
• Countries such as China, India, and Japan are emerging as key markets for laboratory animal models, driven by growing research opportunities, particularly in fields such as cancer research, toxicology testing, and immunological studies
• Japan remains a crucial market, with its advanced medical technology and expanding number of research institutions and pharmaceutical companies utilizing laboratory animal models for preclinical research
• China and India, with their large populations and rising healthcare investments, are seeing increased adoption of laboratory animal models for drug testing, disease modeling, and preclinical studies. These regions are benefiting from both government initiatives and private sector investments, enhancing the overall accessibility to modern research facilities and animal model technology

Laboratory Animal Model Market Share

The market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to market.

The Major Market Leaders Operating in the Market Are:

• Charles River Laboratories (U.S.)
• Labcorp (U.S.)
• Taconic Biosciences, Inc (U.S.)
• Harlan Global Manufacturing, LLC (U.S.)
• The Jackson Laboratory (U.S.)
• genOway (France)
• Bio-Techne (U.S.)
• STEMCELL Technologies (Canada)
• Syngene International Limited (India)
• Axplora (Germany)
• Thermo Fisher Scientific Inc. (U.S.)
• Crown Bioscience (U.S.)
• Biocytogen (China)
• WuXi AppTec (China)

Latest Developments in Global Laboratory Animal Model Market

• In April 2025, the U.S. Food and Drug Administration (FDA) announced a significant transition away from traditional animal testing in drug development. The agency introduced New Approach Methodologies (NAMs), including artificial intelligence-based models and laboratory-engineered human organ-like structures, to enhance drug safety, reduce research and development costs, and minimize animal use. A pilot program will allow selected developers to test antibody-based drugs using NAMs, marking a transformative change in drug evaluation practices 

SKU-73908